Bibliografia UJ CM

1/4
Ruth Ladenstein, Ulrike Pötschger, Andrew D.J. Pearson, Penelope Brock, Roberto Luksch, Victoria Castel, Isaac Yaniv, Vassilios Papadakis, Genevieve Laureys, Josef Malis, Walentyna Balwierz, Ellen Ruud, Per Kogner, Henrik Schroeder, Ana Forjaz De Lacerda, Maja Beck-Popovic, Pavel Bician, Miklós Garami, Toby Trahair, Adela Canete, Peter F. Ambros, Keith Holmes, Mark Gaze, Günter Schreier, Alberto Garaventa, Gilles Vassal, Jean Michon, Dominique Valteau-Couanet.
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.
Lancet. Oncology
2017 : Vol. 18, nr 4, s. 500-514, il., bibliogr. 30 poz., sum.
Autor korespondencyjny: Ruth Ladenstein.
p-ISSN: 1470-2045
AZ
ORG
AIF
IF: 36.418
Adres url:
Streszczenie w PubMed:
2/4
Ruth Ladenstein, Ulrike Poetschger, Martin Elliott, Roberto Luksch, Victoria Castel, Isaac Yaniv, Vassilios Papadakis, Genevieve Laureys, Josef Malis, Walentyna Balwierz, Ellen Ruud, Per Kogner, Henrik Schroeder, Ana Forjaz De Lacerda, Maja Beck Popovic, Pavel Bician, Miklos Garami, Toby Trahair, Andrew D.J. Pearson, Dominique Valteau Couanet.
Prognostic factors in stage 4 neuroblastoma treated with busulphan-melphalan: Report from the European HR-NBIA/Siopen trial.
Journal of Clinical Oncology
2016 : Vol. 34, nr 15 suppl., abstr. 10527.
2016 ASCO Annual Meeting, Chicago, 3-7 June 2016.
p-ISSN: 0732-183X
SZZ
SIF
3/4
Ruth Ladenstein, Ulrike Poetschger, Roberto Luksch, Penelope Brock, Victoria Castel, Isaac Yaniv, Vassilios Papadakis, Genevieve Laureys, Josef Malis, Walentyna Balwierz, Ellen Ruud, Per Kogner, Henrik Schroeder, Ana Forjaz De Lacerda, Maja Beck-Popovic, Pavel Bician, Miklos Garami, Toby Trahair, Peter Ambros, Andrew D.J. Pearson, Dominique Valteau-Couanet, SIOP Europe Neuroblastoma Group.
Major results from the HR-NBL1/SIOPEN trial for high risk neuroblastoma.
Pediatric Blood & Cancer
2012 : Vol. 59, nr 6, s. 988-989, abstr. O069
44th Congress of the International Society of Paediatric Oncology (SIOP), London, United Kingdom, 5th-8th October, 2012
p-ISSN: 1545-5009
SZZ
SIF
4/4
Ruth Ladenstein, Ulrike Poetschger, Roberto Luksch, Penelope Brock, Victoria Castel, Isaac Yaniv, Vassilios Papadakis, Genevieve Laureys, Josef Malis, Walentyna Balwierz, Ellen Ruud, Per Kogner, Henrik Schroeder, Ana Forjaz De Lacerda, Maja Beck-Popovic, Pavel Bician, Miklos Garami, Toby Trahair, Andrew D.J. Pearson, Dominique Valteau-Couanet.
Busulphan-melphalan is the superior myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1/SIOPEN Trial.
Pediatric Blood & Cancer
2011 : Vol. 57, nr 5, s. 733, abstr. O103
43rd Congress of the International Society of Pediatric Oncology (SIOP) 2011, Auckland, New Zealand, 28th-30th October, 2011
p-ISSN: 1545-5009
SZZ
SIF
Wyświetl ponownie stosując format:

Wyświetl/ukryj etykiety | Wyświetlenie wyników w wersji do druku | Pobranie pliku do edytora | Nowe wyszukiwanie | Biblioteka Medyczna UJ